Hemolytic Uremic Syndrome Medical Services in China

Hemolytic Uremic Syndrome (HUS) is a rare, life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It primarily affects the microvasculature—especially in the kidneys—leading to endothelial damage, platelet activation, and fibrin deposition in small arterioles and capillaries. Pathogenesis varies by subtype: Shiga toxin–producing Escherichia coli (STEC-HUS), most commonly linked to E. coli O157:H7 infection following ingestion of undercooked beef or contaminated produce, triggers endothelial injury via ribosomal inactivation and proinflammatory cytokine release. Atypical HUS (aHUS), accounting for ~5–10% of cases, is driven by uncontrolled complement system activation due to genetic mutations (e.g., in CFH, CFI, MCP, C3, or THBD) or autoantibodies against complement regulatory proteins. A third category—secondary HUS—may arise from infections (e.g., pneumococcus), malignancies, autoimmune disorders (e.g., SLE), pregnancy, or certain medications (e.g., calcineurin inhibitors, chemotherapy). Epidemiologically, STEC-HUS peaks in children under 5 years, with an incidence of ~2–3 cases per 100,000 children annually in high-income countries; aHUS has an estimated incidence of 0.2–0.3 per million per year and affects all ages, with median onset in adulthood. Risk factors include young age (for STEC-HUS), inherited complement dysregulation (for aHUS), immunosuppression, recent gastrointestinal illness, and underlying conditions such as hypertension or chronic kidney disease. HUS imposes profound quality-of-life impacts: acute phase symptoms—including pallor, fatigue, oliguria/anuria, edema, seizures, and altered mental status—can necessitate ICU admission, dialysis, and prolonged hospitalization. Survivors often face long-term sequelae: 25–50% develop chronic kidney disease, 3–5% progress to end-stage renal disease requiring transplantation, and neurocognitive deficits, hypertension, and cardiovascular complications may persist. Psychosocial burden includes anxiety, depression, school or work disruption, caregiver strain, and financial hardship—particularly where access to plasma exchange, eculizumab, or specialized nephrology-hematology care is limited. Early recognition and multidisciplinary management involving hematologists, nephrologists, intensivists, and pediatric specialists are critical to mitigating morbidity and mortality.

Hemolytic Uremic Syndrome (HUS) is a thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It arises from endothelial injury in the renal microvasculature, leading to platelet activation, fibrin deposition, and mechanical fragmentation of red blood cells. Etiologically, HUS is broadly classified into Shiga toxin–producing Escherichia coli (STEC)-associated (typical) HUS and atypical HUS (aHUS), which is complement-mediated and often genetically driven.

The most common cause of typical HUS is infection with Shiga toxin–producing *Escherichia coli*, particularly serotype O157:H7, though other serotypes (e.g., O26, O103, O111, O145) are increasingly recognized. STEC produces Shiga toxins (Stx1 and Stx2), which bind globotriaosylceramide (Gb3) receptors on glomerular endothelial cells, inducing apoptosis, proinflammatory cytokine release, and upregulation of adhesion molecules. This triggers platelet aggregation, microthrombi formation, and capillary occlusion—especially in the renal cortex. Less commonly, *Shigella dysenteriae* type 1 infection may precipitate HUS, particularly in endemic regions.

Atypical HUS accounts for approximately 5–10% of cases and is distinguished by absence of preceding diarrheal illness and frequent recurrence or chronicity. It results from uncontrolled activation of the alternative complement pathway due to genetic or acquired dysregulation. Key genetic risk factors include loss-of-function mutations in complement regulatory proteins: *CFH* (complement factor H), *CFI* (complement factor I), *CD46* (membrane cofactor protein, MCP), *THBD* (thrombomodulin), and *C3*; or gain-of-function mutations in *CFB* (complement factor B) or *C3*. Approximately 60% of aHUS patients harbor pathogenic variants in one or more of these genes. Notably, *CFH* mutations confer the highest penetrance and worst prognosis, while *CD46* mutations are associated with lower recurrence risk post-kidney transplantation due to its exclusive expression on host cells.

Acquired triggers of complement-mediated HUS include autoantibodies against factor H (present in ~10% of pediatric aHUS cases), often associated with homozygous deletion of *CFHR1/CFHR3*. Other non-infectious triggers encompass pregnancy (particularly postpartum), malignant hypertension, systemic lupus erythematosus, scleroderma renal crisis, certain medications (e.g., calcineurin inhibitors like cyclosporine and tacrolimus, mitomycin C, quinine, clopidogrel), and solid organ or hematopoietic stem cell transplantation. Infections other than STEC—including *Streptococcus pneumoniae* (via neuraminidase-mediated exposure of T-antigen on RBCs and endothelium), HIV, CMV, and influenza—can also induce HUS through distinct immunologic or endothelial mechanisms.

Environmental and demographic risk factors significantly modulate susceptibility. Young children (<5 years) bear the highest incidence of STEC-HUS, likely due to immature Gb3 receptor expression in the gut and developing immune responses. Geographic and seasonal patterns exist: outbreaks correlate with consumption of undercooked ground beef, unpasteurized dairy or juice, contaminated water, and contact with ruminant animals—especially during summer months. Socioeconomic factors such as limited access to clean water, inadequate food safety infrastructure, and crowded living conditions increase exposure risk. In aHUS, female sex, pregnancy, and postpartum states elevate risk due to hormonal modulation of complement activity and placental endothelial stress. Additionally, individuals with preexisting complement gene variants may remain asymptomatic until exposed to a 'second hit'—such as infection, surgery, or medication—unmasking latent dysregulation.

Comorbidities including chronic kidney disease, diabetes mellitus, and immunosuppression further amplify vulnerability. Critically, early recognition of prodromal symptoms—bloody diarrhea (in STEC-HUS), fatigue, oliguria, pallor, or petechiae—is essential, as delayed intervention increases risks of end-stage renal disease, hypertension, and neurologic complications. While supportive care remains foundational, targeted therapies such as eculizumab (a terminal complement inhibitor) have transformed outcomes in aHUS, underscoring the necessity of prompt etiologic differentiation via stool PCR/culture, complement genetic testing, functional assays (e.g., CH50, AH50), and anti–factor H antibody screening.

Hemolytic Uremic Syndrome (HUS) is a life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI). It predominantly affects children but can occur at any age, with distinct epidemiological and clinical patterns between typical (post-diarrheal) and atypical (non-diarrheal) forms. Early symptoms are often nonspecific and insidious, particularly in atypical HUS, leading to diagnostic delays. In typical HUS—most commonly triggered by Shiga toxin–producing Escherichia coli (STEC), especially serotype O157:H7—early manifestations typically follow a prodromal gastroenteritis phase lasting 3–10 days. Patients present with abdominal cramps, non-bloody or bloody diarrhea (often severe and prolonged), low-grade fever, nausea, and vomiting. Notably, up to 10% of STEC-infected individuals progress to HUS; risk factors include young age (<5 years), antibiotic use during the diarrheal phase (which may increase Shiga toxin release), and host genetic susceptibility. In contrast, early symptoms of atypical HUS (aHUS) lack a clear infectious prodrome and may include fatigue, pallor, decreased urine output (oliguria), unexplained bruising or petechiae, headache, confusion, or mild hypertension—reflecting systemic endothelial injury and early microvascular thrombosis. These symptoms may evolve over days to weeks and are frequently misattributed to viral illness or dehydration.

Typical symptoms emerge as the syndrome progresses and reflect end-organ damage from widespread microthrombi in small vessels, particularly in the renal glomeruli, brain, and gastrointestinal tract. The hallmark hematologic features include MAHA—evidenced clinically by pallor, jaundice (due to unconjugated hyperbilirubinemia), and dark urine (hemoglobinuria)—and thrombocytopenia, manifesting as mucocutaneous bleeding (epistaxis, gingival bleeding, menorrhagia), petechiae, purpura, or ecchymoses. Acute kidney injury is nearly universal in established HUS and presents with oliguria or anuria, periorbital or peripheral edema, hypertension (due to volume overload and renin release), lethargy, and signs of uremia (e.g., nausea, anorexia, pruritus, altered mental status). Neurologic involvement occurs in 20–25% of cases and ranges from headache, irritability, and lethargy to seizures, stroke, coma, or cortical blindness—particularly in severe or rapidly progressive disease. Gastrointestinal complications beyond initial diarrhea may include colonic ischemia, ileus, or hemorrhage. Cardiac manifestations such as arrhythmias or heart failure may arise secondary to electrolyte imbalances (hyperkalemia, metabolic acidosis), hypertension, or direct myocardial microvascular injury.

Accompanying symptoms further underscore multisystem involvement. Fever is common but not universal; it may reflect underlying infection (in typical HUS) or sterile inflammation due to complement dysregulation (in aHUS). Hypertension is observed in 50–75% of patients, driven by renal vasoconstriction, sodium retention, and activation of the renin-angiotensin-aldosterone system. Laboratory findings consistently reveal fragmented red blood cells (schistocytes) on peripheral blood smear, elevated lactate dehydrogenase (LDH), low haptoglobin, increased indirect bilirubin, and reticulocytosis—confirming intravascular hemolysis. Thrombocytopenia is usually moderate to severe (platelet count <150 × 10⁹/L, often <50 × 10⁹/L). Renal parameters show elevated serum creatinine and blood urea nitrogen (BUN), proteinuria (often subnephrotic), microscopic hematuria, and granular or muddy brown casts on urinalysis. Complement studies (e.g., low C3, normal C4, elevated Bb or C3d) and ADAMTS13 activity (>10%) help distinguish HUS from thrombotic thrombocytopenic purpura (TTP).

Complications of HUS can be acute or chronic. Acute complications include anuric renal failure requiring dialysis (in ~50% of pediatric typical HUS and >80% of aHUS), hypertensive encephalopathy, intracranial hemorrhage, myocardial infarction, intestinal perforation, pancreatitis, and disseminated intravascular coagulation (rare). Long-term sequelae affect 30–50% of survivors: chronic kidney disease (CKD), end-stage renal disease (ESRD), persistent hypertension, proteinuria, and neurocognitive deficits—especially in those with prolonged AKI or CNS involvement. Recurrent HUS episodes are characteristic of aHUS, particularly in patients with pathogenic variants in complement regulatory genes (CFH, CFI, CD46, C3, THBD) or autoantibodies against factor H.

Diagnosis relies on integrating clinical presentation, laboratory findings, and exclusion of mimics. Key diagnostic tests include complete blood count with peripheral smear, comprehensive metabolic panel (including creatinine, BUN, LDH, haptoglobin, bilirubin), coagulation studies (PT/aPTT, fibrinogen, D-dimer), urinalysis, stool culture and PCR for STEC (in typical HUS), ADAMTS13 activity assay (to rule out TTP), and complement profiling (C3, C4, CH50, factor H, factor I, anti-factor H antibodies). Genetic testing for complement pathway mutations is indicated in suspected aHUS, especially with family history, recurrent episodes, or onset outside infancy/early childhood. Renal biopsy is rarely required but may demonstrate thrombotic microangiopathy—glomerular capillary wall thickening, double contours ("tram-tracking"), intraluminal platelet-fibrin thrombi, and endothelial swelling—when diagnosis remains uncertain.

Differential diagnosis is critical. TTP must be excluded first due to overlapping features and divergent treatment (plasma exchange vs. complement inhibition); TTP typically presents with more prominent neurologic symptoms, higher fever, and profoundly low ADAMTS13 activity (<10%). Other considerations include disseminated intravascular coagulation (DIC), which shows elevated D-dimer, low fibrinogen, and schistocytes but lacks isolated renal predominance and features consumptive coagulopathy. Systemic lupus erythematosus (SLE)–associated TMA may mimic HUS but demonstrates positive ANA, anti-dsDNA, low complement levels (both C3 and C4), and extrarenal lupus manifestations. Malignant hypertension, scleroderma renal crisis, and drug-induced TMA (e.g., from calcineurin inhibitors, mitomycin C, or quinine) require careful medication and exposure history review. Post-transplant TMA and pregnancy-associated HUS (pre-eclampsia/eclampsia, HELLP syndrome) also fall within the differential and necessitate obstetric or transplant-specific evaluation. Accurate classification guides targeted therapy: supportive care and dialysis for typical HUS; eculizumab or ravulizumab (C5 inhibitors) for aHUS; and urgent plasma exchange for TTP.

Hemolytic Uremic Syndrome (HUS) is a life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It most commonly arises from Shiga toxin–producing Escherichia coli (STEC) infection—particularly serotype O157:H7—in children, though atypical HUS (aHUS), driven by dysregulation of the alternative complement pathway, accounts for a significant proportion of cases in adults and is often recurrent or familial. Management requires prompt recognition, multidisciplinary coordination, and risk-stratified intervention. Treatment strategies are broadly categorized into conservative, pharmacologic, and surgical modalities, with outcomes heavily dependent on early diagnosis and organ support.

Conservative treatment forms the cornerstone of initial management, especially in STEC-HUS. Fluid resuscitation must be judicious: while early isotonic crystalloid infusion helps maintain renal perfusion and mitigate ischemic tubular injury, excessive volume expansion risks pulmonary edema and hypertension, particularly in patients with evolving oliguric acute kidney injury. Strict electrolyte monitoring—including potassium, sodium, calcium, and phosphate—is essential; hyperkalemia may necessitate emergent interventions such as intravenous calcium gluconate, insulin-dextrose, or sodium bicarbonate. Nutritional support should prioritize low-protein, low-sodium, and low-potassium diets during active renal impairment, transitioning gradually as renal function recovers. Blood pressure control is critical; ACE inhibitors or ARBs are generally avoided acutely due to risk of worsening renal perfusion but may be reintroduced cautiously during recovery if proteinuria persists. Close neurologic surveillance is mandatory, given the risk of seizures, stroke, or encephalopathy secondary to hypertension, uremia, or microvascular cerebral injury.

Pharmacologic therapy differs markedly between STEC-HUS and aHUS. In STEC-HUS, antibiotics and antimotility agents are contraindicated, as they may increase Shiga toxin release and worsen outcomes. Plasma exchange (PEX) has limited evidence in typical HUS and is not routinely recommended unless there is overlapping clinical suspicion of thrombotic thrombocytopenic purpura (TTP) or severe neurologic involvement. In contrast, aHUS mandates targeted complement inhibition. Eculizumab—a humanized monoclonal antibody that binds C5 and prevents terminal complement complex formation—is the first-line therapy. Initiated intravenously (900 mg weekly for four weeks, then 1200 mg every two weeks), it rapidly halts microvascular thrombosis, improves platelet counts, and promotes renal recovery. Ravulizumab, a longer-half-life C5 inhibitor, offers equivalent efficacy with extended dosing intervals (every 8 weeks after loading), enhancing outpatient adherence. For patients with anti-CFH autoantibodies, rituximab may be added to suppress autoantibody production. Corticosteroids have no proven benefit in isolated aHUS and are discouraged outside specific autoimmune contexts. Anticoagulation is not indicated, as HUS is not a primary coagulopathy; heparin or warfarin increases bleeding risk without improving microvascular outcomes.

Surgical treatment plays a highly selective role. Kidney biopsy is rarely performed due to bleeding risk in thrombocytopenic patients and is reserved only when diagnosis remains uncertain despite comprehensive serologic, genetic, and functional testing. Dialysis—either intermittent hemodialysis or continuous renal replacement therapy (CRRT)—is required in approximately 50–70% of pediatric STEC-HUS and up to 90% of aHUS cases with severe AKI. CRRT is preferred in hemodynamically unstable or critically ill patients, including those with encephalopathy or multiorgan failure. Surgical nephrectomy is obsolete and contraindicated. In rare refractory aHUS cases with end-stage kidney disease and persistent complement activation, combined liver-kidney transplantation may be considered—primarily for patients with biallelic CFH or CFI mutations where the liver produces defective complement regulators—but carries substantial perioperative morbidity and requires lifelong immunosuppression and continued complement blockade.

China offers distinct advantages in HUS management, particularly through its integrated national rare disease registry and standardized diagnostic pathways endorsed by the National Health Commission. Major academic centers—including Peking University First Hospital, Shanghai Children’s Medical Center, and West China Hospital—maintain high-volume HUS registries with longitudinal genomic and phenotypic data, facilitating rapid differential diagnosis via next-generation sequencing panels covering >20 complement-related genes (CFH, CFI, CD46, THBD, C3, etc.). Eculizumab was approved in China in 2020 and is now accessible under the National Reimbursement Drug List (NRDL), significantly reducing out-of-pocket costs. Moreover, China’s centralized plasma exchange networks and CRRT-capable ICUs in tier-3 hospitals ensure timely organ support across urban and semi-urban regions. Telemedicine platforms enable real-time consultation between provincial hematologists and national experts, minimizing diagnostic delays. Importantly, Chinese guidelines emphasize early pediatric referral and discourage inappropriate antibiotic use in diarrheal illness—contributing to lower mortality rates (<3% in STEC-HUS at leading centers versus global averages of 5–10%).

Recovery advice must be individualized and longitudinal. Patients recovering from STEC-HUS require serial monitoring of renal function (eGFR, urinalysis, albumin-to-creatinine ratio), blood pressure, and hematologic parameters for at least 12 months; late-onset hypertension and proteinuria may emerge years later. Those with aHUS need indefinite follow-up, including serum C3, C4, CH50, and soluble C5b-9 levels, with eculizumab continuation guided by biomarker trends and clinical stability. Vaccination against encapsulated organisms (e.g., pneumococcus, meningococcus, Haemophilus influenzae type B) is mandatory prior to complement inhibition due to overwhelming post-splenectomy–like infection risk. Patients should avoid NSAIDs, which impair renal perfusion, and receive genetic counseling if pathogenic variants are identified. Psychosocial support—including school reintegration planning for children and vocational counseling for adults—is integral. Long-term renal prognosis varies: ~70% of STEC-HUS survivors regain full renal function, whereas ~50% of aHUS patients progress to chronic kidney disease stage 3 or higher without sustained complement blockade. With modern therapeutics, 5-year patient survival exceeds 95% in specialized centers, underscoring the importance of timely referral to hematologic and nephrologic expertise.